1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generics in Europe, MarketLine

Generics in Europe, MarketLine

  • January 2016
  • -
  • MarketLine
  • -
  • 32 pages

Introduction

Generics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Europe generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

- The European generics market is expected to generate total revenues of $57.4bn in 2015, representing a compound annual growth rate (CAGR) of 6.2% between 2011 and 2015.

- Market consumption volume is forecast to reach a total of 70.7% of total pharma volume in 2015.

- The European market is dominated by markets with high generic uptake, including those in Western Europe, such as the UK and Germany, as well as those in Eastern Europe, such as Russia and Poland. However, markets such as France and Norway provide scope for the generics market to grow.

Features

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Europe

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Europe

- Leading company profiles reveal details of key generics market players’ global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Europe generics market with five year forecasts by both value and volume

- Macroeconomic indicators provide insight into general trends within the Europe economy

Key Questions Answered

- What was the size of the Europe generics market by value in 2015?

- What will be the size of the Europe generics market in 2020?

- What factors are affecting the strength of competition in the Europe generics market?

- How has the market performed over the last five years?

- How large is Europe’s generics market in relation to its regional counterparts?

Table Of Contents

Generics in Europe, MarketLine
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Mylan Inc. 19
Sandoz International GmbH 22
Sanofi SA 23
Teva Pharmaceutical Industries Limited 26
Methodology 29
Industry associations 30
Related MarketLine research 30
Appendix 31
About MarketLine 31

List of Tables
Table 1: Europe generics market value: $ billion, 2011-15(e)
Table 2: Europe generics market volume: % of total pharma volume, 2011-15(e)
Table 3: Europe generics market geography segmentation: $ billion, 2015(e)
Table 4: Europe generics market value forecast: $ billion, 2015-20
Table 5: Europe generics market volume forecast: % of total pharma volume, 2015-20
Table 6: Mylan Inc.: key facts
Table 7: Mylan Inc.: key financials ($)
Table 8: Mylan Inc.: key financial ratios
Table 9: Sandoz International GmbH: key facts
Table 10: Sanofi SA: key facts
Table 11: Sanofi SA: key financials ($)
Table 12: Sanofi SA: key financials (€)
Table 13: Sanofi SA: key financial ratios
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures
Figure 1: Europe generics market value: $ billion, 2011-15(e)
Figure 2: Europe generics market volume: % of total pharma volume, 2011-15(e)
Figure 3: Europe generics market geography segmentation: % share, by value, 2015(e)
Figure 4: Europe generics market value forecast: $ billion, 2015-20
Figure 5: Europe generics market volume forecast: % of total pharma volume, 2015-20
Figure 6: Forces driving competition in the generics market in Europe, 2015
Figure 7: Drivers of buyer power in the generics market in Europe, 2015
Figure 8: Drivers of supplier power in the generics market in Europe, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Europe, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in Europe, 2015
Figure 11: Drivers of degree of rivalry in the generics market in Europe, 2015
Figure 12: Mylan Inc.: revenues and profitability
Figure 13: Mylan Inc.: assets and liabilities
Figure 14: Sanofi SA: revenues and profitability
Figure 15: Sanofi SA: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

North America Insulin Delivery Market Outlook to 2022

North America Insulin Delivery Market Outlook to 2022

  • $ 5995
  • Industry report
  • January 2017
  • by Global Data

North America Insulin Delivery Market Outlook to 2022 Summary GlobalData’s new report, "North America Insulin Delivery Market Outlook to 2022", provides key market data on the North America Insulin Delivery ...

North America Vision Care Market Outlook to 2022

North America Vision Care Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by Global Data

North America Vision Care Market Outlook to 2022 Summary GlobalData’s new report, "North America Vision Care Market Outlook to 2022", provides key market data on the North America Vision Care market. ...


Download Unlimited Documents from Trusted Public Sources

Global Therapy Market

  • January 2017
    32 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • World  

View report >

Insulin Market and Diabetes Statistics in the US

  • January 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Diabetes Statistics

  • January 2017
    10 pages
  • Diabetes  

    Therapy  

View report >

Related Market Segments :

Pharmaceutical

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.